Mind Medicine Australia & Drug Science Collaborate to Teach the Fundamentals of Psychedelic-Assisted Therapies to International Audiences
Mind Medicine Australia, August 1, 2024
Mind Medicine Australia (MMA) is excited to announce our collaboration with Drug Science to update our popular Fundamentals of Psychedelic-Assisted Therapies training programme for an international cohort.
Optimi Health Secures Import Permit from Mind Medicine Australia for MDMA and Psilocybin Capsules
Globe News Wire, May 29, 2024
Company preparing to export 160 doses of MDMA and psilocybin under Australia’s Authorized Prescriber Scheme.
Andrew Robb Backs Campaign For Realistic Access To Psychedelic Therapies In NSW
Mind Medicine Australia, March 13, 2024
Given the mental health crisis facing Australia, the former Federal Coalition Minister, Andrew Robb, today called on all NSW State Parliamentarians to demand urgent amendments to NSW Health Department regulations.
Mind Medicine Australia, Marks 5-Year Milestone with Global Achievements in Psychedelic Therapies
Mind Medicine Australia, February 12, 2024
Mind Medicine Australia (MMA), a trailblazing charitable organisation in mental health advocacy and innovation, proudly celebrates its 5th Anniversary this week. Over the past five years, MMA has been at the forefront of transformative progress in the field of psychedelic-assisted therapies in Australia and internationally.
Psychiatrists give the First Psychedelic Medicine Dosing Sessions in Clinical Settings in 50 Years this Week in Melbourne Australia
Mind Medicine Australia, January 19, 2024
This week the first two patients received treatment with psychedelic-assisted therapies as part of the Therapeutic Goods Administration’s (TGA) Authorised Prescriber (AP) program in Melbourne, Australia with medicines and training supplied through Mind Medicine Australia.
World Renowned Dr Ben Sessa (UK) to visit Australia in October 2023 to lead training and education for Psychedelic-Assisted Therapies
Mind Medicine Australia, October 18, 2023
Mind Medicine Australia (MMA) is delighted to bring leading psychedelic researchers Dr Ben Sessa (Bristol, UK) and Dr Lauren Macdonald (London, UK) to Australia this October and November to lead the residential training for MMA’s leading Certificate in Psychedelic-Assisted Therapies (CPAT) program.
New Overseas Trial Results Strongly Support the TGA’s Decision to Reschedule the controlled Use of MDMA and Psilocybin for Mental Illness
Mind Medicine Australia, September 26, 2023
On 3rd February 2023 the TGA announced the restricted rescheduling of MDMA and Psilocybin as Schedule 8 Controlled Medicines when used as part of therapy for patients with post-traumatic stress disorder (MDMA) or treatment resistant Depression (psilocybin). As part of the decision the TGA acknowledged the current lack of treatment options for patients suffering from these mental illnesses which can cause immense suffering. It is therefore highly relevant that two major trials, which have just published their results in leading medical journals, provide further support for the use of these medicines in the controlled conditions envisaged by the TGA.
Psychedelic-Assisted Therapies are about to be available in Australia. What Does This Mean for Australia’s Mental Healthcare System?
Mind Medicine Australia, June 26, 2023
In just a few days psychiatrists will be able to apply to become Authorised Prescribers of MDMA and psilocybin. Authorised Prescribers will be able to prescribe these substances as part of therapy, in controlled clinical settings for patients with treatment-resistant depression (psilocybin) and treatment resistant post-traumatic stress disorder (MDMA).
The Enormous “Elephant in the Room” in assessing the Government’s Budget Announcement of a $2.3 billion increase to Mental Health Funding
Mind Medicine Australia, May 13, 2023
Mind Medicine Australia (MMA) welcomes the Government’s commitment to mental health and its drive to improve the mental health of Australians and reduce suicide rates. The increased funding for the sector announced in the Budget is an especially important part of this.
Leading Psychedelic Medicine Psychiatrist Coming to Australia
Mind Medicine Australia, April 17, 2023
British Psychiatrist and Leading Psychedelic Medicine Specialist, Educator and Author – Dr Ben Sessa – to visit Australia, present Public Lectures and Lead the Residential Training for Students in Mind Medicine Australia’s Upcoming Certificate in Psychedelic-Assisted Therapies (CPAT) Course.
Announcement of Funding for Two New Research Projects to Test the Effects of Psychedelic Medicines for Obsessive Compulsive Disorder (OCD) and in Group Situations
Mind Medicine Australia, March 20, 2023
Mind Medicine Australia is delighted to announce that it is funding two new research projects by the ANU School of Medicine and Psychology and a team led by Professor Paul Fitzgerald, Associate Professor Bernadette Fitzgibbon and Dr Neil Bailey, to broaden our understanding of the effectiveness and application of psychedelic medicines.
Major Announcements about Mind Medicine Australia’s Certificate in Psychedelic-Assisted Therapies (CPAT)
Mind Medicine Australia, February 28, 2023
Mind Medicine Australia Outlines its Next Steps for Psychedelic Assisted Therapies in Australia following the TGA’s Rescheduling Announcement for the Medical Use of Psilocybin and MDMA. In 2023 the program will be taken to a whole new level, with the engagement of an International Course Director Dr Gita Vaid MD (USA). In addition to this Dr Eli Kotler (AUS) has taken on the role of Australian Course Director and Dr Lauren Macdonald (UK) will also join the International Faculty.
Next Steps for Psychedelic Assisted Therapies in Australia following the TGA’s Rescheduling Announcement for the Medical Use of Psilocybin and MDMA
Mind Medicine Australia, February 7, 2023
Mind Medicine Australia Outlines its Next Steps for Psychedelic Assisted Therapies in Australia following the TGA’s Rescheduling Announcement for the Medical Use of Psilocybin and MDMA
Breaking News: The TGA Announces the Delegate’s Final Decision to Reschedule the Use of Psilocybin and MDMA for Medical Purposes
Mind Medicine Australia, February 3, 2023
Earlier today, the Therapeutic Goods Administration (TGA) announced that – from the 1st July 2023 – the medical use of MDMA and Psilocybin will be rescheduled from Schedule 9 (prohibited substances) to Schedule 8 (controlled medicines) of the Poisons Standard. This will enable authorised psychiatrists to prescribe these substances for treatment-resistant depression and treatment resistant post-traumatic stress disorder.
An Urgent Opportunity to Help Fix Australia’s Broken Mental Health System by Supporting Psychedelic-Assisted therapies
Mind Medicine Australia, November 22, 2022
Australia’s mental health system is broken. Rates of mental illness and addiction are skyrocketing, leading to immense suffering and suicide in this nation. Even pre-Covid, Australia’s mental illness statistics were the second worst of all OECD nations, only ahead of Iceland!
This broken system has led to thousands of Australians with treatment-resistant mental illness. Franco Bortolin is a prime example of the reality for people with severe treatment-resistant mental illness.
An Open Letter To The Prime Minister
Mind Medicine Australia, November 10, 2022
Vanessa Bortolin Delivers a Letter to the Prime Minister Anthony Albanese, Telling The Story of Her Husband’s Suicide and Requesting His Assistance In Creating A New Treatment Pathway For People With Treatment Resistant Depression By Allowing Limited Access To Psychedelic-Assisted therapies.
She shared the tragic story of her husband, who lost his life to suicide after a 3-year battle with treatment-resistant depression, leaving behind his wife of 30 years, Vanessa, and their beloved daughter Zara.
Use of Psychedelic Therapies for Treatment Resistant Patients Again Rejected by Government, Despite Strong Supporting Safety and Efficacy Data, Massive Public Support and Australia’s Worsening Mental Health Crisis
Mind Medicine Australia, October 28, 2022
Mind Medicine Australia (MMA) will prepare a detailed submission to the Therapeutic Goods Administration (TGA) following the Delegate’s “disappointing” decision not to include the limited medical use of MDMA and Psilocybin therapies in Schedule 8 of the Poison’s Standard, despite strongly supporting safety and efficacy results from overseas trials and strong controls
World Renowned Professor David Nutt (UK) to visit Australia in November 2022 to build awareness of Psychedelic-Assisted Therapies
Mind Medicine Australia, October 5, 2022
Mind Medicine Australia (MMA) is delighted to bring Professor David Nutt from Imperial College London to Australia to educate Australians about psychedelic-assisted therapies and endorse fair access to these life-saving treatments. His International Keynote is entitled ‘Psychedelic-Assisted Therapies: History, Neuroscience and Myths’.
Victorian Government Proposes Controversial Regulatory Change Amidst Worsening Mental Health Crisis
Mind Medicine Australia, September 6, 2022
The Victorian Government has proposed a controversial change in health regulations to take away its current ability to issue permits for the clinical use of pharmaceutical grade MDMA and Psilocybin as part of psychotherapy for treatment resistant patients. MMA is one of several organisations and individuals that have lodged submissions outlining key reasons why the proposed regulatory change should not proceed.
Mind Medicine Australia announces a new fund to support the development of observational trials into psychedelic-assisted therapies in Australia for key classes of mental illness to better understand their translation into widespread clinical practice
Mind Medicine Australia, August 23, 2022
Mind Medicine Australia (MMA) is excited to announce a new fund to support the development of observational trials into psychedelic-assisted therapies to treat a range of mental illnesses. The initial commitment of funding of $1 million will be provided by the Hunt Family Foundation with additional funding sought from other philanthropists.
Download (242.2 KB)